ENTITY
Akeso Biopharma Inc

Akeso Biopharma Inc (9926 HK)

211
Analysis
Health CareChina
Akeso Inc. operates operatesa s a biotech company. The compnay develops treatments and therapies for various types of diseases. Akeso serves cutomers worldwide
more
19 Apr 2022 08:54

Sino Biopharmaceutical (1177.HK) - Three “Golden Eggs” and the Risks Behind

Sino Biopharma is lucky to have three “golden eggs”  to contribute huge performance over the years. But its weak pipeline and other destabilizing...

Logo
361 Views
Share
02 Apr 2022 19:32

Shanghai Junshi Bioscience (1877 HK): Uncertainties Prevailing Ahead of First U.S. Drug Approval

Going by the FDA’s recent action, Junshi Bioscience’s toripalimab has a chance to get rejected by the FDA. It may miss the approval timeline....

Logo
339 Views
Share
28 Mar 2022 08:59

Akeso Biopharma Inc (9926.HK) - Caution Is Advised Until Sufficient Financing Is Secured

Akeso has a high starting point, with strong R&D capability and valuable pipeline. However, related clinical trials will drain money fast....

Logo
276 Views
Share
06 Mar 2022 09:09

China Healthcare Weekly (Mar.4)-Innovative Drug Cyclical Nature, Pet Vaccine Mkt, Legend Bio, Junshi

Junshi’s PD-1 result in April is more representative to judge FDA's attitude and globalization logic. We probably are at the tail end of mab drug...

Logo
260 Views
Share
13 Feb 2022 09:12

China Healthcare Weekly (Feb.11)- “14th Five-Year Plan” For Medical Beauty, Wuxi Biologics, Innovent

We analyzed the “14th Five-year Plan”  for medical beauty, the impact of WuXi Bio after being included in "unverified list" and the prospects of...

Logo
269 Views
Share
x